References
- Akavein N, Oettinger CW, Gayakwad SG, Addo RT, Bejugam NK, Bauer JT, Do D, Plollock SH, D'Souza MJ. Treatment of adjuvant arthritis using microencapsulated antisense NF-κB oligonucleotides. J Microencapsulation 2008; 18: 1–12
- Akerlund K, Harris HE, Tracey KJ, Wang H, Fehniger L, Klareskog L, Andersson J, Andersson J, Andersson U. Anti-inflammatory effects of a new tumor necrosis factor-alpha (TNF-a) inhibitor (CNI-1493) in collagen induced (CIA) in rats. Clin Exp Immunol 1999; 115: 32–41
- Bianchi M, Bloom O, Raabe T, Cohen PS, Chesney J, Sherry B, Schmidtmayerova H, Calandra T, Zhang X, Bukrinsky M, et al. Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone. J Exp Med 1996; 83: 927–936
- Bianchi M, Ulrich P, Bloom O, Meistrell M, Zimmerman GA, Schmidtmaykyerova H, Bukrinsky M, Donnelley T, Bucala R, Sherry B, et al. An inhibitor of macrophage arginine transport and nitric oxide production (CNI-1493) prevents acute inflammation and endotoxin lethality. Molec Med 1995; 1: 254–266
- Bjork L, Tracey KJ, Ulrich P, Bianchi M, Cohen PS, Akerlund K, Fehniger TE, Andersson U, Andersson J. Targeted suppression of cytokine production in monocytes but not in T lymphocytes by a tetravalent guanylhydrazone (CNI-1493). J Infect Dis 1997; 176: 1303–1312
- Cohen PS, Nakshatri H, Dennis J, Caragine T, Bianchi M, Cerami A, Tracey K. CNI-1493 inhibits monocyte/macrophage tumor necrosis factor by suppression of translation efficiency. Proc Natl Acad Sci USA 1996; 93: 3967–3971
- D'Souza MJ, Oettinger CW, Milton GV. Microspheres containing neutralizing antibodies to tumor necrosis factor α and interleukin-1β protect rats from Staphylococcus aureus-induced peritonitis. J Interferon Cytokine Res 2000; 20: 907–913
- D'Souza MJ, Oettinger CW, Milton GV, Tracey KJ. Prevention of lethality and suppression of pro-inflammatory cytokines in experimental septic shock by microencapsulated CNI-1493. J Interferon Cytokine Res 1999; 1: 1125–1133
- D'Souza MJ, Zhaowei J, Oettinger CW. Treatment of experimental septic shock with microencapsulated antisense oligomers to NF-kB. J Interferon Cytokine Res 2005; 25: 311–320
- Oettinger CW, D'Souza MJ. Microencapsulation of tumor necrosis factor oligomers: A new approach to pro-inflammatory cytokine inhibition. J Interferon Cytokine Res 2003; 23: 533–544
- Oettinger CW, D'Souza MJ, Akavein N, Peer GT, Taylor FB, Kinasewitz GT. Pro-inflammatory cytokine inhibition in the primate using microencapsulated antisense oligomers to NF-kB. J Microencapsulation 2007; 24: 337–348
- Oettinger CW, D'Souza MJ, Milton GV. Targeting macrophages with microspheres containing cytokine-neutralizing antibodies prevents lethality in gram negative peritonitis. J Interferon Cytokine Res 1999; 19: 33–40
- Okusawa S, Gelfand J, Ikejima T. Interleukin-1 induces a shock-like state in rabbits. Synergism with tunor mecrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest. 1988; 81: 1162–1172
- Pahl HL. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 1999; 18: 6853–6866